{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:34:15Z","timestamp":1788878055746,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.vaccine.2020.07.018","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T17:47:15Z","timestamp":1596131235000},"page":"6007-6018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus"],"prefix":"10.1016","volume":"38","author":[{"given":"Yuhong","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Schante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Buchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Russell","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart N.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.07.018_b0005","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.vaccine.2020.07.018_b0010","doi-asserted-by":"crossref","first-page":"16262","DOI":"10.1073\/pnas.1005769107","article-title":"Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo","volume":"107","author":"Rimoin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2020.07.018_b0015","doi-asserted-by":"crossref","DOI":"10.9734\/IJTDH\/2017\/35885","article-title":"Evolution of a disease surveillance system: an increase in reporting of human monkeypox disease in the democratic republic of the Congo, 2001\u20132013","volume":"25","author":"Hoff","year":"2017","journal-title":"Int J Trop Dis Health"},{"key":"10.1016\/j.vaccine.2020.07.018_b0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/14787210.2019.1567330","article-title":"Monkeypox re-emergence in Africa: a call to expand the concept and practice of One Health","volume":"17","author":"Reynolds","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.vaccine.2020.07.018_b0025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.vaccine.2006.09.046","article-title":"An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies","volume":"25","author":"Wiser","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.018_b0030","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nm916","article-title":"Clonal vaccinia virus grown in cell culture as a new smallpox vaccine","volume":"9","author":"Weltzin","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.07.018_b0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/13543784.17.4.555","article-title":"ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine","volume":"17","author":"Greenberg","year":"2008","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.vaccine.2020.07.018_b0040","unstructured":"CDC. Progressive vaccinia in a military smallpox vaccinee -- United States, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:532-6."},{"key":"10.1016\/j.vaccine.2020.07.018_b0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14760584.8.1.13","article-title":"IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine","volume":"8","author":"Kennedy","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.07.018_b0050","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.07.018_b0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.07.018_b0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.07.018_b0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.07.018_b0070","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0075","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0080","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.018_b0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","article-title":"Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host","volume":"345","author":"Fang","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.07.018_b0090","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0095","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","article-title":"A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost","volume":"25","author":"Xiao","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.018_b0100","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1073\/pnas.0701451104","article-title":"Smallpox subunit vaccine produced in planta confers protection in mice","volume":"104","author":"Golovkin","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2020.07.018_b0105","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/j.vaccine.2006.12.037","article-title":"Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges","volume":"25","author":"Fogg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.018_b0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.virol.2007.01.001","article-title":"Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge","volume":"362","author":"Thornburg","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.07.018_b0115","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/JVI.01854-07","article-title":"Vaccination of BALB\/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge","volume":"82","author":"Berhanu","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0120","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1128\/JVI.00353-08","article-title":"Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice","volume":"82","author":"Kaufman","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0125","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.vaccine.2009.09.133","article-title":"Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates","volume":"28","author":"Hooper","year":"2009","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.07.018_b0130","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1016\/j.vaccine.2010.07.030","article-title":"A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge","volume":"28","author":"Buchman","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.018_b0135","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1016\/j.vaccine.2010.05.023","article-title":"Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection","volume":"28","author":"Rudraraju","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.018_b0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virol.2011.08.005","article-title":"Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge","volume":"419","author":"Clark","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.07.018_b0145","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.vaccine.2012.11.007","article-title":"Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide\/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge","volume":"31","author":"Xiao","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.018_b0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1743-422X-10-229","article-title":"Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response","volume":"10","author":"Paran","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2020.07.018_b0155","doi-asserted-by":"crossref","unstructured":"Reeman S, Gates AJ, Pulford DJ, Krieg A, Ulaeto DO. Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant. Viruses. 2017;9.","DOI":"10.3390\/v9120378"},{"key":"10.1016\/j.vaccine.2020.07.018_b0160","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1128\/JVI.00568-08","article-title":"Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge","volume":"82","author":"Fogg","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0165","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.07.018_b0170","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.07.018_b0175","unstructured":"Centers for Disease C, Prevention. Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:642-6."},{"key":"10.1016\/j.vaccine.2020.07.018_b0180","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1056\/NEJMoa032299","article-title":"The detection of monkeypox in humans in the Western Hemisphere","volume":"350","author":"Reed","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.07.018_b0185","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.38.1800509","article-title":"Two cases of monkeypox imported to the United Kingdom, September 2018","volume":"23","author":"Vaughan","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2020.07.018_b0190","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S1473-3099(19)30537-7","article-title":"A case of imported Monkeypox in Singapore","volume":"19","author":"Ng","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.07.018_b0195","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1016\/j.vaccine.2010.05.007","article-title":"Preformulation studies\u2013The next advance in aluminum adjuvant-containing vaccines","volume":"28","author":"Hem","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.018_b0200","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2020.07.018_b0205","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.018_b0210","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1128\/JVI.00852-08","article-title":"Vaccinia virus l1 protein is required for cell entry and membrane fusion","volume":"82","author":"Bisht","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0215","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/JVI.72.5.4192-4204.1998","article-title":"The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus","volume":"72","author":"Roper","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0220","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1126\/science.1183173","article-title":"Repulsion of superinfecting virions: a mechanism for rapid virus spread","volume":"327","author":"Doceul","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.07.018_b0225","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/JVI.02152-12","article-title":"Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine","volume":"87","author":"Benhnia","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0230","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1099\/vir.0.043943-0","article-title":"Protein B5 is required on extracellular enveloped vaccinia virus for repulsion of superinfecting virions","volume":"93","author":"Doceul","year":"2012","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.07.018_b0235","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","article-title":"Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin","volume":"325","author":"Bell","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.07.018_b0240","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/nm1457","article-title":"Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination","volume":"12","author":"Putz","year":"2006","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:46:24Z","timestamp":1759401984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20309312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":48,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0264410X20309312"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}